References
- CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- HurdSThe impact of COPD on lung health worldwide: epidemiology and incidenceChest20001172 Suppl1S4S10673465
- LeeHKimJTagmazyanKTreatment of stable chronic obstructive pulmonary disease: the GOLD guidelinesAm Fam Physician20138810655663663B663F24364481
- SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax200863759259818245142
- AaronSDVandemheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
- FrithPAThompsonPJRatnavadivelRGlisten Study GroupGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
- SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
- HarrellAWSiedererSKBalJMetabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humansDrug Metab Dispos20134118910023043183
- LötvallJBatemanEDBusseWWComparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroidsJ Negat Results Biomed2014131924928338
- KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPLoS One2012712e5071623284643
- SalterMBiggadikeKMatthewsJLPharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory diseaseAm J Physiol Lung Cell Mol Physiol20072933L660L66717575011
- BrealeyNGuptaARenauxJMehtaRAllenAHendersonAPharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteersInt J Clin Pharmacol Ther201553975376426227101
- SilerTMKerwinESousaARDonaldAAliRChurchAEfficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studiesRespir Med201510991155116326117292
- FeldmanGMaltaisFKhindriSA randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPDInt J Chron Obstruct Pulmon Dis20161171973027103795
- ChurchABeeraheeMBrooksJMehtaRShahPDose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over studyBMC Pulm Med201414224393134
- GSKRegulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD2016 Available from: http://www.gsk.com/en-gb/media/press-releases/2016/regulatory-update-on-us-filing-plans-for-closed-triple-combination-therapy-ffumecvi-in-patients-with-copd/Accessed October 29, 2016
- KrigsmanKNilssonJLRingLRefill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptionsPharmacoepidemiol Drug Saf200716444144817006959
- BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
- MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
- WedzichaJABanerjiDChapmanKRFLAME InvestigatorsIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606